We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
80 hedge funds and large institutions have $123M invested in Crescent Biopharma in 2020 Q3 according to their latest regulatory filings, with 7 funds opening new positions, 23 increasing their positions, 31 reducing their positions, and 13 closing their positions.
New
Increased
Maintained
Reduced
Closed
1,004% more call options, than puts
Call options by funds: $2.9M | Put options by funds: $263K
0.09% less ownership
Funds ownership: 0.93% → 0.84% (-0.09%)
8% less funds holding
Funds holding: 87 → 80 (-7)
19% less capital invested
Capital invested by funds: $152M → $123M (-$29.1M)
26% less repeat investments, than reductions
Existing positions increased: 23 | Existing positions reduced: 31
46% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 13
Holders
80
Holders Change
-7
Holders Change %
-8.05%
% of All Funds
1.61%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
7
Increased
23
Reduced
31
Closed
13
Calls
$2.9M
Puts
$263K
Net Calls
+$2.64M
Net Calls Change
+$2.47M
Top Buyers
Top Sellers
| 1 |
Wellington Management Group
Boston,
Massachusetts
|
-$3.37M |
| 2 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
-$1.91M |
| 3 |
Morgan Stanley
New York
|
-$1.37M |
| 4 |
Renaissance Technologies
New York
|
-$1.25M |
| 5 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$691K |
